TY  - CHAP
M1  - Book, Section
TI  - Chapter 157. Scleroderma
A1  - Moinzadeh, P.
A1  - Denton, Christopher P.
A1  - Krieg, T.
A1  - Black, Carol M.
A2  - Goldsmith, Lowell A.
A2  - Katz, Stephen I.
A2  - Gilchrest, Barbara A.
A2  - Paller, Amy S.
A2  - Leffell, David J.
A2  - Wolff, Klaus
Y1  - 2012
N1  - 
T2  - Fitzpatrick's Dermatology in General Medicine, 8e
AB  - |PrintSynopsis  at  a  GlanceSystemic  sclerosis  (SSc)  is  a  multisystemic  disease,  characterized  by  excessive  fibrosis,  inflammation,  and  vasculopathy.The  pathogenesis  of  this  autoimmune  process  remains  unclear.Differential  diagnosis  of  SSc  includes  severe  forms  of  localized  scleroderma  as  well  as  many  other  scleroderma-like  conditions.Patients  with  SSc  are  classified  into  two  major  subtypes  depending  on  the  extent  of  skin  sclerosis  [diffuse  systemic  sclerosis  (dSSc)  and  limited  systemic  sclerosis  (lSSc)].  Patients  with  an  overlap  syndrome,  are  characterized  by  additional  clinical  features  of  other  rheumatic  diseases.Raynaud  phenomenon  (RP)  and  skin  sclerosis  are  almost  always  present.SSc  is  defined  by  sclerotic/fibrotic  alterations  of  the  skin  and  internal  organs  (digestive  tract,  lung,  kidney,  and  heart),  which  can  lead  to  severe  dysfunction  of  almost  any  visceral  organ.The  heterogeneity  and  clinical  course  of  SSc  requires  the  urgent  need  of  interdisciplinary  collaborations  and  regular,  at  least  yearly,  follow-up  visits.Although  the  disease  is  still  not  curable,  there  have  been  substantial  advances  in  therapy  for  organ-based  complications  of  SSc.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/24
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56076922
ER  -